Patents by Inventor Ramil Baiazitov

Ramil Baiazitov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS
    Publication number: 20220064150
    Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Application
    Filed: November 10, 2021
    Publication date: March 3, 2022
    Inventors: Chang-Sun Lee, Ramil Baiazitov, Liangxian Cao, Thomas W. Davis, Wu Du, Ronggang Liu, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Substituted reverse pyrimidine Bmi-1 inhibitors
    Patent number: 11180483
    Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: November 23, 2021
    Assignee: PTC Therapeutics, Inc.
    Inventors: Chang-Sun Lee, Ramil Baiazitov, Liangxian Cao, Thomas W. Davis, Wu Du, Ronggang Liu, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Substituted pyridine and pyrazine BMI-1 inhibitors
    Patent number: 10584115
    Abstract: Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: March 10, 2020
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Ramil Baiazitov, Soongyu Choi, Wu Du, Seongwoo Hwang, Chang-Sun Lee, Ronggang Liu, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS
    Publication number: 20200024260
    Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Application
    Filed: September 26, 2019
    Publication date: January 23, 2020
    Inventors: Chang-Sun Lee, Ramil Baiazitov, Liangxian Cao, Thomas W. Davis, Wu Du, Ronggang Liu, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Substituted reverse pyrimidine Bmi-1 inhibitors
    Patent number: 10428050
    Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: October 1, 2019
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Chang-Sun Lee, Ramil Baiazitov, Liangxian Cao, Thomas W Davis, Wu Du, Ronggang Liu, Young-choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Substituted pyrimidine Bmi-1 inhibitors
    Patent number: 10370371
    Abstract: Amine substituted pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: August 6, 2019
    Assignee: PTC Therapeutics, Inc.
    Inventors: Wu Du, Ramil Baiazitov, Chang-Sun Lee, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • Substituted triazine BMI-1 inhibitors
    Patent number: 9975878
    Abstract: Amine substituted triazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: May 22, 2018
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Hiroo Koyama, Ramil Baiazitov, Wu Du, Chang-sun Lee, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko
  • SUBSTITUTED TRIAZINE BMI-1 INHIBITORS
    Publication number: 20160297798
    Abstract: Amine substituted triazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Application
    Filed: November 21, 2013
    Publication date: October 13, 2016
    Inventors: Hiroo Koyama, Ramil Baiazitov, Wu Du, Chang-sun Lee, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko
  • SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS
    Publication number: 20160280685
    Abstract: Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Application
    Filed: November 21, 2013
    Publication date: September 29, 2016
    Inventors: Ramil Baiazitov, Soongyu Choi, Wu Du, Seongwoo Hwang, Chang-Sun Lee, Ronggang Liu, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • SUBSTITUTED PYRIMIDINE BMI-1 INHIBITORS
    Publication number: 20160214978
    Abstract: Amine substituted pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Application
    Filed: November 21, 2013
    Publication date: July 28, 2016
    Inventors: Wu Du, Ramil Baiazitov, Chang-Sun Lee, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
  • SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS
    Publication number: 20150315182
    Abstract: Amine substituted reverse pyrimidine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
    Type: Application
    Filed: November 21, 2013
    Publication date: November 5, 2015
    Inventors: Chang-Sun Lee, Ramil Baiazitov, Liangxian Cao, Thomas W Davis, Wu Du, Ronggang Liu, Young-choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde